| Sector |
Healthcare
|
Compare with Sector peers |
| Industry |
Pharmaceuticals & Drugs
|
Compare with Industry peers |
| Website | http://www.panchsheel.com | |
| Financial Indicators | ||
|---|---|---|
| Market Cap | 47.77 Cr. | |
| Earnings per share (EPS) | 9.98 | Trailing Twelve Months Ending 2021-03 |
| Price-Earning Ratio (PE) | 9.54 | Trailing Twelve Months Ending 2021-03 |
| Industry PE | 35.17 | Trailing Twelve Months Ending 2021-03 |
| Book Value / Share | 79.13 | Trailing Twelve Months Ending 2021-03 |
| Price to Book Value | 1.20 | Calculated using Price: 95.25 |
| Dividend Yield | 0.00 | Period Ending 2020-03 |
| No. of Shares Subscribed | 0.50 Cr. | 5,015,400 Shares |
| FaceValue | 10 | |
| Company Profile | ||
|
Panchsheel Organics, incorporated in the year 1989, is a part of the Pharmaceutical Division of the Turakhia Brothers Group. Turakhia Brothers was founded in 1975 in the Mumbai, India. The Turakhia Group, promoters of the company, are engaged in the import-export trade of pharmaceutical raw materials since the past 25 years. Panchsheel exports bulk actives to over 60 countries mainly in Europe, South East Asia, Japan and Latin America. The company's inherent strength lies in identifying relevant bulk drugs and selling them at affordable prices across the world. Skilled people, modern equipment and broad experience contribute to the strength of Panchsheel Organics. Skilled production teams assure flexibility, efficiency and consistent standard in drugs manufacturing. The R & D division of Panchsheel backed with experienced, highly qualified teams provide sophisticated innovative solutions. Skilled production teams assure flexibility, efficiency and consistent standard in chemical manufacturing. The current practices at Panchsheel are adherence to high quality and safety standards as well as full compliance with GMP procedures. The gaseous emissions are properly controlled and waste water is treated properly so as to ensure compliance with local and international risk, minimizing damage to persons and environment. Panchsheel has free capacity in its five production sites in all over India. This capacity is would be used by interested companies for development and custom synthesis on strictly confidential terms. Some of the basic operations carried out by Panchsheel are:
Product range of the company includes: |
||
Company Profile
Panchsheel Organics, incorporated in the year 1989, is a part of the Pharmaceutical Division of the Turakhia Brothers Group. Turakhia Brothers was founded in 1975 in the Mumbai, India. The Turakhia Group, promoters of the company, are engaged in the import-export trade of pharmaceutical raw materials since the past 25 years.
Panchsheel exports bulk actives to over 60 countries mainly in Europe, South East Asia, Japan and Latin America. The company's inherent strength lies in identifying relevant bulk drugs and selling them at affordable prices across the world.
Skilled people, modern equipment and broad experience contribute to the strength of Panchsheel Organics. Skilled production teams assure flexibility, efficiency and consistent standard in drugs manufacturing.
The R & D division of Panchsheel backed with experienced, highly qualified teams provide sophisticated innovative solutions. Skilled production teams assure flexibility, efficiency and consistent standard in chemical manufacturing.
The current practices at Panchsheel are adherence to high quality and safety standards as well as full compliance with GMP procedures. The gaseous emissions are properly controlled and waste water is treated properly so as to ensure compliance with local and international risk, minimizing damage to persons and environment.
Panchsheel has free capacity in its five production sites in all over India. This capacity is would be used by interested companies for development and custom synthesis on strictly confidential terms.
Some of the basic operations carried out by Panchsheel are:
Product range of the company includes: Bulk Drugs - Alendronate Sodium Trihydrate, Isoxsuprine HCL, Alprazolam, Itraconazole Pellets 22%, Amitriptyline HCL BP/USP, Ketoconazole BP/USP, Amlodipine Besylate etc.
| 1 Day |
|
-2.06% |
| 1 Week |
|
-6.80% |
| 1 Month |
|
-2.46% |
| 3 Month |
|
+5.66% |
| 6 Month |
|
+10.24% |
| 1 Year |
|
+75.90% |
| 2 Year |
|
+72.87% |
| 5 Year |
|
+19.81% |
| 9 years | 2012-03 | 2013-03 | 2014-03 | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | |
| Return on Equity (%) | 12.37 | 8.01 | 10.49 | 10.55 | 15.43 | 14.48 | 14.57 | 14.05 | 16.08 | |
| Return on Capital Employed (%) | 15.05 | 11.05 | 15.09 | 14.28 | 18.51 | 19.66 | 18.21 | 17.77 | 20.31 | |
| Return on Assets (%) | 6.50 | 4.11 | 5.22 | 5.55 | 8.66 | 8.43 | 8.55 | 8.76 | 10.79 |
| Particulars | 9 years | 2012-03 Rs. Cr. | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. |
| Shh. Funds | 16 | 16 | 18 | 19 | 21 | 23 | 27 | 30 | 35 | |
| Non Curr. Liab. | 3 | 2 | 3 | 4 | 4 | 2 | 1 | 0 | 1 | |
| Curr. Liab. | 11 | 14 | 15 | 11 | 12 | 14 | 19 | 15 | 17 | |
| Minority Int. | ||||||||||
| Equity & Liab. | 30 | 32 | 35 | 33 | 37 | 39 | 47 | 45 | 53 | |
| Non Curr. Assets | 8 | 8 | 8 | 7 | 9 | 10 | 10 | 9 | 11 | |
| Curr. Assets | 22 | 24 | 27 | 26 | 28 | 29 | 37 | 36 | 42 | |
| Misc. Exp. not W/O | ||||||||||
| Total Assets | 30 | 32 | 35 | 33 | 37 | 39 | 47 | 45 | 53 |
| Particulars | 9 years | 2012-03 Rs. Cr. | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. |
| Net Sales | 30 | 33 | 39 | 36 | 40 | 40 | 42 | 48 | 51 | |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Total Income | 30 | 33 | 39 | 36 | 41 | 40 | 42 | 49 | 51 | |
| Total Expenditure | -27 | -30 | -35 | -31 | -35 | -33 | -36 | -41 | -42 | |
| PBIDT | 4 | 3 | 5 | 5 | 6 | 7 | 7 | 7 | 9 | |
| Interest | -1 | -1 | -1 | -1 | -1 | 0 | -1 | 0 | 0 | |
| Depreciation | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | |
| Taxation | -1 | -1 | -1 | -1 | -1 | -2 | -2 | -2 | -2 | |
| Exceptional Items | ||||||||||
| PAT | 2 | 1 | 2 | 2 | 3 | 3 | 4 | 4 | 5 |
| Particulars | 9 years | 2012-03 Rs. Cr. | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. |
| Cash Fr. Operatn. | 1 | 1 | 3 | 1 | 3 | 5 | 3 | 2 | 5 | |
| Cash Fr. Inv. | 0 | -1 | -1 | -1 | -2 | -3 | -1 | -1 | -3 | |
| Cash Fr. Finan. | -2 | 0 | -2 | 0 | -1 | -1 | -2 | -2 | -1 | |
| Net Change | -1 | 0 | 0 | 0 | -1 | 0 | 0 | 0 | 1 | |
| Cash & Cash Eqvt | 0 | 0 | 1 | 0 | 1 | 1 | 0 | 1 | 2 |
|
Thu, 15 Jul 2021
Shareholding for the Period Ended June 30 2021 Panchsheel Organics Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30 2021. For more details kindly Click here |
||||||||||||||
|
Fri, 09 Jul 2021
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Please note that we have received information from M/s. Purva Sharegistry (I) Private Limited our Registrar and Share Transfer Agent via email dated July 8 2021 (attached herewith) regarding loss of share certificates and request for issuance of duplicate share certificates as detailed below: Sr. No. Folio No. Name of the Shareholder Certificate No. Distinctive No. No. of shares From To From To 1. K00784 Kokila Shah Jatin Shah 0035268 0035268 3496201 3496300 100 0044828 0044828 4452201 4452300 100 0045334 0045336 4502801 4503100 300 This information is being submitted pursuant to Regulation 39(3) of the SEBI (Listing Obligations & Disclosure Requirements) Regulations 2015. This is for your information and records only. |
||||||||||||||
|
Wed, 07 Jul 2021
Statement Of Investor Complaints For The Quarter Ended June 2021
|
| Fri, 23 Jul 2021 |
Stock Underperforming Benchmark Index in both 1 Week and 3 Month
|
Stock Underperforming Sectoral Index in both 1 Week and 3 Month
|
Close Within 2 Year High Zone
|
Both SRS And ARS Above Zero
|
Close Crossing 50 EMA From Above
|
Equities
M.F.
Sectors